Neoadjuvant high-dose intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration in patients with stage IIIa-IVa cervical cancer.

经皮盆腔灌注下新辅助大剂量动脉灌注化疗联合体外化学滤过治疗 IIIa-IVa 期宫颈癌患者。

• 批准号: 15390506
• 负责人: MOTOYAMA Satoru
• 金额: $ 5.12万
• 依托单位: Kobe University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (B)
• 财政年份: 2003
• 资助国家: 日本
• 起止时间: 2003 至 2005
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-15390506/
• 关键词: uterine cervical carcinoma; neoadjuvant chemotherapy; chemoflltration; high dose chemotherapy; intraarteial infusion; 術前化学療法; 高用量; ダウンステージ; PPPEC; 子宮頚癌; 抗癌剤毒性; HPV; CDDP; 体外循環; STD

The objective of this study was to evaluate the response rate and survival of patients with locally advanced uterine cervical cancer who were treated with intraarterial infusion chemotherapy under percutaneous pelvic perfusion with extracorporeal chemofiltration (PPPEC). Twenty three previously untreated patients with stage IIIa-IVa cervical cancer were enrolled in the study.PPPEC was administered twice at 2 weeks interval using super high-dose cisplatin alone (140-250mg/m^2) or super high-dose cisplatin plus mitomycin C (10mg/body), pepleomycin (10mg/body) and 5-fluorouracil (1000mg/body). Eighteen patients with confirmed tumor down-staging underwent radical surgery following PPPEC. Radiotherapy was administered on the remaining five patients. Two weeks aI~er the second PPPEC, the median volumetric tumor reduction and tumor response were 76.4% and 86.9%, respectively Histologic response was 95.6% while the tumor down-staging reached 82.6%. The curative surgery rate achieved was 88.9%. Five-year progression-free survival was 47.4% and 5-year survival rate was 73.7%.As conclusion, Super high-dose intraarterial infusion chemotherapy under PPPEC effectively achieved tumor down-staging and resulted in the favorable performance of the subsequent radical surgery hence improved the 5-year survival rate of patients with locally advanced uterine cervical cancer.

本研究的目的是评价局部晚期宫颈癌患者接受经皮盆腔灌注联合体外化学滤过（PPPEC）动脉灌注化疗的缓解率和生存率。选择23例未经治疗的Ⅲ a ~ Ⅳ a期宫颈癌患者，PPPEC单用超大剂量顺铂（140- 250 mg/m2）或超大剂量顺铂联合丝裂霉素C（10 mg/例）、培洛霉素（10 mg/例）和5-氟尿嘧啶（1000 mg/例），间隔2周，共2次。18例确诊为肿瘤降级的患者在PPPEC后接受了根治性手术。其余5名患者接受了放射治疗。第二次PPPEC后2周，中位肿瘤体积缩小率为76.4%，肿瘤有效率为86.9%，组织学有效率为95.6%，肿瘤分期下降率为82.6%。手术治愈率为88.9%。5年无进展生存率为47.4%，5年生存率为73.7%，PPPEC下超大剂量动脉灌注化疗可有效降低肿瘤分期，提高局部晚期宫颈癌患者的5年生存率。

项目成果

laminin-5γ2 Chain and Matrix Metalloproteinase-2 Expression in the Neoplastic changes of Uterine Carvical Squamous Epithelium.

层粘连蛋白-5γ2 链和基质金属蛋白酶-2 在子宫宫颈鳞状上皮肿瘤变化中的表达。

• 发表时间: 2004
• 期刊: Kobe Journal of Medical Science. 50
• 作者: Shibata K;et al.;RobinMalina
• 通讯作者: RobinMalina

Lack of association between endometriosis and the CYP 17 MspA1 polymorphisms in UK and Japanese populations

英国和日本人群子宫内膜异位症与 CYP 17 MspA1 多态性之间缺乏关联

• 发表时间: 2005
• 期刊: Gynecologic Endocrinology 20
• 作者: Asghar T;Yoshida S;Nakago S;Morizane M;Ohara N;Motoyama S;Kennedy S;Barrow D;Maruo T
• 通讯作者: Maruo T

Transient increase in squamous cell carcinoma antigen expression in cultured cervical carcinoma Caski cells in response to exposure to Cisdiamminedichloroplatinum.

培养的宫颈癌 Caski 细胞中鳞状细胞癌抗原表达因暴露于顺二氯铂而短暂增加。

• 发表时间: 2004
• 期刊: TUMOR BIOLOGY 24
• 作者: Tateiwa Y;Yoshida S;Miyahara Y;Hamana S;Motoyam SMaruo T
• 通讯作者: Motoyam SMaruo T

Lack of association between endometriosis And N-acetyltransferase 1(NAT1)and 2(NAT2) Polymorphism in a Japanese population

日本人群中子宫内膜异位症与 N-乙酰转移酶 1(NAT1) 和 2(NAT2) 多态性之间缺乏关联

• 发表时间: 2005
• 期刊: Journal of Society for Gynecologic Investigation (In press)(未定)
• 作者: Nomura M;et al.;Deguchi M
• 通讯作者: Deguchi M

Neoadjuvant High-dose Intraarterial Infusion Chemotherapy under Percutaneous Pelvic Perfusion with Extracorporeal Chemofiltration In Patients with Stage IIIa-IVa Cervical Cancer.

IIIa-IVa 期宫颈癌患者经皮盆腔灌注联合体外化学滤过的新辅助大剂量动脉内灌注化疗。

• 发表时间: 2004
• 期刊: Gynecologic Oncology 95
• 作者: Motoyama S;Hamana S;Ku Y;Fernandez J;Deguchi M;Yoshida S;Tominaga M;Iwasaki T;Ohara N;Maruo T.
• 通讯作者: Maruo T.